Howson, Zhengda Sunny, Huahai "grab" antihypertensive drugs! Shandong pharmaceutical enterprises into the bureau

On November 19, CDE's official website showed that Shandong Kongfu Pharmaceutical's Anli Shengtan tablet was accepted with a generic 4-class application for listing.
recent years, China's public medical institutions terminal Anli shengtan film sales grew rapidly, in the first half of this year year increased by more than 200% year-on-year, more than the sales for the whole of last year.
the product's domestic manufacturers are Jiangsu Haussen Pharmaceuticals, Zhengda Tianqing Pharmaceuticals, Zhejiang Huahai Pharmaceuticals three.
, Wuhan People's Fu Pharmaceuticals, Jiangsu Jiayi Pharmaceuticals, Jiangsu Deyuan Pharmaceuticals submitted market applications in the same category as 4, in the review and approval (in the drug review center).
data show that The Enrhotret tablets are mainly used to treat patients with Pulmonary hypertension with WHOII.grade or III.
2020H1 China's public medical institutions terminal Anlisheng Tan brand pattern Source: China's public medical institutions terminal competition pattern Mi intranet data show that in recent years in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal Anlisheng Tan film sales growth, in the first half of this year increased by more than 200% year-on-year, more than the sales of the whole of last year.
note that GlaxoSmithKline's market share has fallen rapidly, from its exclusive market in 2017 to 87 per cent in 2019, with less than 60 per cent in the first half of this year, with the approval of domestic pharmaceutical companies.
source: Mi Net one-click search up to now, Andison Tan tablets domestic manufacturers have Jiangsu Hausen Pharmaceuticals, Zhengda Tianqing Pharmaceuticals, Zhejiang Huahai Pharmaceuticals three.
source: MED2.0 China Drug Review Database Prior to this, Wuhan People's Fu Pharmaceuticals, Jiangsu Jiayi Pharmaceuticals, Jiangsu Deyuan Pharmaceuticals submitted listing applications in the same category as 4 categories, in the review and approval (in the Drug Review Center).
source: CDE website, Minet database